HELM INTELLIGENCEGILD
Preparing your analysis.
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Working on your request
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Investors may consider Gilead's strong EPS growth and pipeline developments while evaluating their own investment strategies.
Gilead Sciences, Inc. has a market capitalization of $182.39B and is currently priced at $145.33, reflecting a 1.11% increase from the previous close of $143.73. The company reported a significant year-over-year EPS growth of 1684.21%, while its revenue growth stands at 2.40%. The P/E ratio is 21.44, with a P/S ratio of 6.19, and a dividend yield of 2.19%. Gilead's 52-week trading range is between $109 and $157.27.
Some investors cite Gilead's stellar EPS growth of 1684.21% as a strong indicator of its profitability potential. Additionally, the company's long-term growth prospects in HIV treatments are bolstered by the recent launch of Sunlenca, which could drive future revenue.
Conversely, Gilead's revenue growth of only 2.40% may raise concerns about its ability to sustain momentum in a competitive market. Furthermore, the company has experienced larger stock price drops compared to the general market, indicating potential volatility.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Gilead Sciences, Inc. has a market capitalization of $182.39B and is currently priced at $145.33, reflecting a 1.11% increase from the previous close of $143.73. The company reported a significant year-over-year EPS growth of 1684.21%, while its revenue growth stands at 2.40%. The P/E ratio is 21.44, with a P/S ratio of 6.19, and a dividend yield of 2.19%. Gilead's 52-week trading range is between $109 and $157.27.
Conversely, Gilead's revenue growth of only 2.40% may raise concerns about its ability to sustain momentum in a competitive market. Furthermore, the company has experienced larger stock price drops compared to the general market, indicating potential volatility.
Some investors cite Gilead's stellar EPS growth of 1684.21% as a strong indicator of its profitability potential. Additionally, the company's long-term growth prospects in HIV treatments are bolstered by the recent launch of Sunlenca, which could drive future revenue.
Some investors cite Gilead's stellar EPS growth of 1684.21% as a strong indicator of its profitability potential. Additionally, the company's long-term growth prospects in HIV treatments are bolstered by the recent launch of Sunlenca, which could drive future revenue. Conversely, Gilead's revenue growth of only 2.40% may raise concerns about its ability to sustain momentum in a competitive market. Furthermore, the company has experienced larger stock price drops compared to the general market, indicating potential volatility.
Gilead Sciences, Inc. has a market capitalization of $182.39B and is currently priced at $145.33, reflecting a 1.11% increase from the previous close of $143.73. The company reported a significant year-over-year EPS growth of 1684.21%, while its revenue growth stands at 2.40%. The P/E ratio is 21.44, with a P/S ratio of 6.19, and a dividend yield of 2.19%. Gilead's 52-week trading range is between $109 and $157.27.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for GILD at helmterminal.dev/analyze/GILD, updated continuously during US market hours. No signup required.